Jonathan Robert Seckl

USPTO Granted Patents = 14 (Patent Applications = 1)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 4.2

ph-index = 7

Forward Citations = 273(Granted Patents)

Location History:

Lothian, GB (2013)
Edinburgh, GB (2002 - 2017)

Company Filing History:

13 out of 168

The University of Edinburgh

patents

1 out of 250

Btg International Limited

patents

Years Active: 2002-2017

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9834549 - 3,3-disubstituted-(8-aza-bicyclo[3.2.1]OCT-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11 (β)-HSD1 (2017-12-05),

2. 9365564 - 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11 (β)-HSD1 (2016-06-14),

3. 8642621 - (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use (2014-02-04),

4. 8614209 - Amido-thiophene compounds and their use (2013-12-24),

5. 8362008 - Amido-thiophene compounds and their use as 11-beta-HSD1 inhibitors (2013-01-29),

6. 8299063 - Amido-thiophene compounds and their use (2012-10-30),

7. 7129231 - Regulation of intracellular glucocorticoid concentrations (2006-10-31),

8. 7122532 - Regulation of intracellular glucocorticoid concentrations (2006-10-17),

9. 7122531 - Regulation of intracellular glucocorticoid concentrations (2006-10-17),

10. 7087400 - Regulation of intracellular glucocorticoid concentrations (2006-08-08),

11. 6946487 - Regulation of intracellular glucocorticoid concentrations (2005-09-20),

12. 6838253 - Regulation of intracellular glucocorticoid concentrations (2005-01-04),

13. 6420353 - Use of 7 &agr;-substituted steroid to treat neuropsychiatric, immune or endocrine disorders (2002-07-16),

14. 6368816 - Regulation of intracellular glucocorticoid concentrations (2002-04-09),

Title: The Innovative Mind of Jonathan Robert Seckl

Introduction

Jonathan Robert Seckl, located in Edinburgh, Great Britain, is an esteemed inventor known for his significant contributions to the field of therapeutic compounds. With 14 patents to his name, he has dedicated his career to developing innovative solutions for various health challenges.

Latest Patents

Among his most recent patents are groundbreaking compounds that function as inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). These innovative compounds, such as the 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanones, are designed to tackle serious health issues. They have the potential to treat a range of disorders like metabolic syndrome, type 2 diabetes, obesity, insulin resistance, hypertension, and even CNS disorders such as mild cognitive impairment and Alzheimer's disease. The innovative approaches taken in these patents establish a strong link between biochemical research and practical applications in medicine.

Career Highlights

Jonathan has a distinguished career, with notable work experiences at reputable organizations such as the University of Edinburgh and BTG International Limited. His research has significantly influenced the development of therapeutic compounds focused on combating pressing health concerns.

Collaborations

Throughout his impressive career, Jonathan has collaborated with esteemed colleagues including Brian Robert Walker and Christopher Richard Watkin Edwards. Their combined efforts have led to advancements in the understanding and treatment of numerous medical conditions.

Conclusion

Jonathan Robert Seckl's innovative contributions to the field of therapeutics underscore the importance of research and invention in improving health outcomes. With a remarkable portfolio of 14 patents, he continues to pave the way for advancements in medical therapies, promising a healthier future for many. His work serves as an inspiration to aspiring inventors and researchers in the health sciences.

This text is generated by artificial intelligence and may not be accurate.